FDA Clears C2N's PrecivityAD2 Blood Test for Early Alzheimer's Detection
Event summary
- FDA cleared C2N Diagnostics' PrecivityAD2 blood test for adults as young as 40 with cognitive impairment.
- The clearance marks the first FDA-cleared Alzheimer's blood test for this age group.
- ADDF's $7 million investment through its Diagnostics Accelerator (DxA) supported the test's development.
- PrecivityAD2 is part of ADDF's portfolio of 47 active diagnostic programs.
- 83% of active Alzheimer's trials now incorporate biomarkers, reshaping trial design.
The big picture
The FDA clearance of PrecivityAD2 underscores the rapid advancement of blood-based diagnostics in Alzheimer's care, driven by sustained early investment. This shift towards precision medicine is reshaping clinical trials and paving the way for earlier detection and treatment. The ADDF's long-term commitment to biomarker science highlights the growing momentum in translating lab innovations into clinical tools.
What we're watching
- Diagnostic Adoption
- How quickly PrecivityAD2 and similar blood tests will be integrated into mainstream clinical practice.
- Trial Efficiency
- Whether the increased use of biomarkers will accelerate Alzheimer's drug development timelines.
- Precision Medicine
- The pace at which multi-marker panels and AI-driven diagnostics will enable tailored treatment strategies.
Related topics